Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
Microbot Medical (Nasdaq: MBOT) announced the acceptance of a late-breaking abstract for presentation at the Society of Interventional Radiology (SIR) annual meeting in Nashville from March 29 - April 2, 2025. The presentation will feature first-time data from the ACCESS-PVI trial, a prospective, multicenter, single-arm study evaluating the performance and safety of the LIBERTY® Endovascular Robotic System in peripheral vascular interventions.
The presentation titled 'Remote-controlled endovascular navigation with a miniature, single-use, robotic system. Results of the ACCESS-PVI trial' will be delivered by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center on April 2, 2025. The company views this acceptance as significant since the conference attendees represent potential LIBERTY® system users.
Microbot Medical (Nasdaq: MBOT) ha annunciato l'accettazione di un abstract in ritardo per la presentazione alla riunione annuale della Society of Interventional Radiology (SIR) a Nashville dal 29 marzo al 2 aprile 2025. La presentazione presenterà dati inediti dal trial ACCESS-PVI, uno studio prospettico, multicentrico e a braccio singolo che valuta le prestazioni e la sicurezza del sistema robotico endovascolare LIBERTY® negli interventi vascolari periferici.
Il titolo della presentazione sarà 'Navigazione endovascolare controllata a distanza con un sistema robotico miniaturizzato e monouso. Risultati del trial ACCESS-PVI' e sarà presentato dal Dr. Francois Cornelis del Memorial Sloan Kettering Cancer Center il 2 aprile 2025. L'azienda considera questa accettazione come significativa poiché i partecipanti alla conferenza rappresentano potenziali utilizzatori del sistema LIBERTY®.
Microbot Medical (Nasdaq: MBOT) anunció la aceptación de un resumen tardío para presentación en la reunión anual de la Society of Interventional Radiology (SIR) en Nashville del 29 de marzo al 2 de abril de 2025. La presentación incluirá datos por primera vez del ensayo ACCESS-PVI, un estudio prospectivo, multicéntrico y de brazo único que evalúa el desempeño y la seguridad del Sistema Robótico Endovascular LIBERTY® en intervenciones vasculares periféricas.
La presentación titulada 'Navegación endovascular controlada a distancia con un sistema robótico miniatura y de un solo uso. Resultados del ensayo ACCESS-PVI' será realizada por el Dr. Francois Cornelis del Memorial Sloan Kettering Cancer Center el 2 de abril de 2025. La empresa considera esta aceptación como significativa, ya que los asistentes a la conferencia representan a potenciales usuarios del sistema LIBERTY®.
Microbot Medical (Nasdaq: MBOT)는 2025년 3월 29일부터 4월 2일까지 내슈빌에서 열리는 중재 방사선 학회 (SIR) 연례 회의에서 발표하기 위해 늦게 발표된 초록이 채택되었다고 발표했습니다. 이번 발표에서는 말초 혈관 개입에서 LIBERTY® 혈관 로봇 시스템의 성능과 안전성을 평가하는 전향적, 다기관, 단일 군 연구인 ACCESS-PVI 시험의 최초 데이터를 다룰 것입니다.
'소형 일회용 로봇 시스템을 이용한 원격 제어 혈관 탐색. ACCESS-PVI 시험 결과'라는 제목의 발표는 2025년 4월 2일 Memorial Sloan Kettering Cancer Center의 Francois Cornelis 박사에 의해 진행될 것입니다. 이 회사는 이 수용을 중요한 것으로 간주하고 있으며, 회의 참석자들은 잠재적인 LIBERTY® 시스템 사용자로서의 가치를 지닙니다.
Microbot Medical (Nasdaq: MBOT) a annoncé l'acceptation d'un résumé tardif pour une présentation lors de la réunion annuelle de la Society of Interventional Radiology (SIR) à Nashville du 29 mars au 2 avril 2025. La présentation mettra en avant des données inédites de l'essai ACCESS-PVI, une étude prospective, multicentrique et à bras unique évaluant la performance et la sécurité du Système Robotique Endovasculaire LIBERTY® dans les interventions vasculaires périphériques.
La présentation intitulée 'Navigation endovasculaire télécommandée avec un système robotique miniature et à usage unique. Résultats de l'essai ACCESS-PVI' sera présentée par le Dr. Francois Cornelis du Memorial Sloan Kettering Cancer Center le 2 avril 2025. L'entreprise considère cette acceptation comme significative car les participants à la conférence représentent des utilisateurs potentiels du système LIBERTY®.
Microbot Medical (Nasdaq: MBOT) hat die Annahme eines späten Abstracts für die Präsentation auf dem Jahreskongress der Society of Interventional Radiology (SIR) in Nashville vom 29. März bis 2. April 2025 bekannt gegeben. Die Präsentation wird erstmalige Daten aus der ACCESS-PVI-Studie präsentieren, einer prospektiven, multizentrischen, einarmigen Studie zur Evaluierung der Leistung und Sicherheit des LIBERTY® Endovaskulären Robotersystems bei peripheren Gefäßinterventionen.
Die Präsentation mit dem Titel 'Fernsteuerbare endovaskuläre Navigation mit einem miniaturisierten, einmal verwendbaren Robotersystem. Ergebnisse der ACCESS-PVI-Studie' wird am 2. April 2025 von Dr. Francois Cornelis vom Memorial Sloan Kettering Cancer Center gehalten. Das Unternehmen betrachtet diese Annahme als bedeutend, da die Teilnehmer der Konferenz potenzielle Nutzer des LIBERTY®-Systems repräsentieren.
- Acceptance of late-breaking abstract at major industry conference (SIR)
- First-time presentation of ACCESS-PVI trial data
- Direct exposure to potential customers at conference
- None.
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics
BRAINTREE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025. The data from the Company’s ACCESS-PVI trial, a prospective, multicenter, single-arm trial evaluating the performance and safety of LIBERTY® in patients undergoing peripheral vascular interventions, will be presented for the first time at a podium presentation.
- Abstract/Presentation Title: Remote-controlled endovascular navigation with a miniature, single-use, robotic system. Results of the ACCESS-PVI trial
- Presenter: Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology.
- Location: Music City Center, Nashville, TN
- Date/Time: Wednesday, April 2, 11:33 AM - 11:42 AM CT
“We believe the acceptance of this late breaking news is critically important and allows the Principal Investigators (PI) to present the data for the first time at the SIR annual meeting, especially since the primary attendees at this conference are potential users of LIBERTY®,” commented Harel Gadot, Chairman, CEO and President. “In addition, we believe that the potential benefits of LIBERTY® will be meaningful and significant to the audience.”
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
When will Microbot Medical (MBOT) present its ACCESS-PVI trial results?
What is the focus of Microbot Medical's (MBOT) ACCESS-PVI trial?
Who will present Microbot Medical's (MBOT) ACCESS-PVI trial data at SIR 2025?
What is the significance of MBOT's late-breaking abstract acceptance at SIR 2025?
